Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Rare Tumor × Vemurafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 4 Multiple Myeloma 3 Hematologic Neoplasms 3 Thyroid Cancer, Papillary 2 Neoplasms by Site 2 Neoplasms by Histologic Type 2 Melanoma 2 Lymphoma, Non-Hodgkin 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Thyroid Carcinoma, Anaplastic 1 Rare Tumor 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Lymphoproliferative Disorders 1 Leukemia, Hairy Cell 1 Laryngeal Neoplasms 1 Glioma 1 Erdheim-Chester Disease 1 Colorectal Cancer Metastatic 1 Adenocarcinoma, Follicular 1

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡